News

A new study entitled “Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer’s disease brains” identified genomic changes in single neurons as an underlying mechanism in sporadic Alzheimer’s disease. The study was published in the journal…

A recent study found that preparing foods at high temperatures might increase the risk of Alzheimer’s disease. The results were published in the current issue of the Journal of Alzheimer’s Disease. The research team from The Icahn School of Medicine at Mount Sinai examined studies that assessed…

The Harry T. Mangurian Jr. Foundation has granted the Mayo Clinic in Jacksonville, Florida, a $5.75 million gift to fund research on Lewy body dementia. Mayo will be launching a new program dedicated to advancing knowledge on diseases that cause a…

According to a recent study from a team of researchers at Tel Aviv University, a mutation in a specific neuroprotective protein called ADNP has different expressions between males and females. This research adds new insights to what is currently known about the etiology of autism and Alzheimer’s disease. The results…

Many health practitioners recommend a glass of red wine a day to promote health benefits. But what about beer? A recent study published by researchers at Lanzhou University in China explores the possibility that beer may also promote health. The article, titled “Xanthohumol, a Polyphenol Chalcone Present in…

Ft. Lauderdale, Florida based Bluvision has announced a collaborative venture with wearable technologies innovator GTX Corp., a company that specializes in the development of personal location devices, to create solutions for location tracking those with memory cognitive disorders like Alzheimer’s and other forms of Dementia, as well as persons…

Congressman Chaka Fattah recently met with Amarantus, a biotechnology firm specializing in discovering and developing treatments and diagnostics for Alzheimer’s disease and other degenerative brain conditions, to discuss ongoing and future neurologic research strategies. Gerald Commissiong, the CEO of Amarantus, and Robert Farrell, the CFO, had briefed Congressman…

One of the biggest challenges that research and development in the field of Alzheimer’s Disease faces is not the discovery of new treatment candidates, but the lack of funding to advance these discoveries into human testing. In addition, very few funding sources address early-phase clinical drug trials and, as a…

A researcher from the University of Oklahoma is currently developing a new therapy to address Alzheimer’s disease by using biopharmaceutical proteases. The goal is to target the harmful amyloid beta plaque that builds up in the brains of AD patients. If successful, the scientist expects this approach to be cheaper, and…

Amarantus BioScience Holdings, Inc., a biotechnology company committed to developing diagnostics in neurology and to advance therapeutic products in several areas such as neurology, ophthalmology, psychiatry and regenerative medicine, recently announced the formation of an Alzheimer’s disease Diagnostics Scientific Advisory Board (SAB). The company also designated three renowned experts in Alzheimer’s disease and neurological disorders as its first members: Paula…